Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

a Phase I/IIa, Open Label, Uncontrolled Study to Evaluate the Safety and Efficacy of Astarabine (BST-236) as Single Agent in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Disease

Next Previous
Search
Trial Profile

a Phase I/IIa, Open Label, Uncontrolled Study to Evaluate the Safety and Efficacy of Astarabine (BST-236) as Single Agent in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Disease

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspacytarabine (Primary)
  • Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Acronyms BSTPHASE1-01
  • Sponsors BioSight

Most Recent Events

  • 07 Dec 2020 According to a BioSight media release, Integrated Results(n=61) from a Phase 1/2a and an Ongoing Phase 2b of BST-236 were presented at 61st Annual Meeting of the American Society of Hematology (ASH)
  • 07 Dec 2020 Results published in a BioSight media release.
  • 19 Nov 2019 According to a BioSight media release, Integrated Results from a Phase 1/2a and an Ongoing Phase 2b of BST-236 will be presented at 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL on December 7, 2019

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top